Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Antibodies, Viral"" wg kryterium: Temat


Tytuł:
Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines.
Autorzy:
Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Addetia A; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Dang HV; Vir Biotechnology, San Francisco, CA 94158, USA.
Stewart C; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Brown JT; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Sharkey WK; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Sprouse KR; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Walls AC; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA.
Mazzitelli IG; Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Buenos Aires C1121ABG, Argentina.
Logue JK; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA.
Franko NM; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA.
Czudnochowski N; Vir Biotechnology, San Francisco, CA 94158, USA.
Powell AE; Vir Biotechnology, San Francisco, CA 94158, USA.
Dellota E Jr; Vir Biotechnology, San Francisco, CA 94158, USA.
Ahmed K; Departments of Paediatrics and Child Health and Biological and Biomedical Sciences, Aga Khan University, Karachi 74800, Pakistan.
Ansari AS; Departments of Paediatrics and Child Health and Biological and Biomedical Sciences, Aga Khan University, Karachi 74800, Pakistan.
Cameroni E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Gori A; Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.; Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy.
Bandera A; Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.; Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy.
Posavad CM; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Dan JM; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA 92037, USA.
Zhang Z; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Weiskopf D; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Sette A; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA 92037, USA.
Crotty S; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA 92037, USA.
Iqbal NT; Departments of Paediatrics and Child Health and Biological and Biomedical Sciences, Aga Khan University, Karachi 74800, Pakistan.
Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Geffner J; Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Buenos Aires C1121ABG, Argentina.
Snell G; Vir Biotechnology, San Francisco, CA 94158, USA.
Grifantini R; INGM, Istituto Nazionale Genetica Molecolare 'Romeo ed Enrica Invernizzi,' Milan, Italy.
Chu HY; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA.
Veesler D; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2022 Aug 19; Vol. 377 (6608), pp. 890-894. Date of Electronic Publication: 2022 Jul 19.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Neutralizing*/blood
Antibodies, Neutralizing*/immunology
Antibodies, Viral*/blood
Antibodies, Viral*/immunology
COVID-19*/blood
COVID-19*/prevention & control
COVID-19 Vaccines*/immunology
SARS-CoV-2*/immunology
Spike Glycoprotein, Coronavirus*/genetics
Spike Glycoprotein, Coronavirus*/immunology
Humans ; Immunization, Secondary
SCR Organism:
SARS-CoV-2 variants
Czasopismo naukowe
Tytuł:
ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies.
Autorzy:
Low JS; Institute for Research in Biomedicine, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland.; Institute of Microbiology, ETH Zürich, 8093 Zurich, Switzerland.
Jerak J; Institute for Research in Biomedicine, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland.; Institute of Microbiology, ETH Zürich, 8093 Zurich, Switzerland.
Tortorici MA; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
McCallum M; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Pinto D; Humabs BioMed SA (subsidiary of Vir Biotechnology), 6500 Bellinzona, Switzerland.
Cassotta A; Institute for Research in Biomedicine, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland.
Foglierini M; Institute for Research in Biomedicine, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland.
Mele F; Institute for Research in Biomedicine, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland.
Abdelnabi R; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium.
Weynand B; KU Leuven Department of Imaging and Pathology, Translational Cell and Tissue Research, B-3000 Leuven, Belgium.
Noack J; Vir Biotechnology, San Francisco, CA 94158, USA.
Montiel-Ruiz M; Vir Biotechnology, San Francisco, CA 94158, USA.
Bianchi S; Humabs BioMed SA (subsidiary of Vir Biotechnology), 6500 Bellinzona, Switzerland.
Benigni F; Humabs BioMed SA (subsidiary of Vir Biotechnology), 6500 Bellinzona, Switzerland.
Sprugasci N; Humabs BioMed SA (subsidiary of Vir Biotechnology), 6500 Bellinzona, Switzerland.
Joshi A; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Stewart C; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Rexhepaj M; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Walls AC; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Howard Hughes Medical Institute, Seattle, WA 98195, USA.
Jarrossay D; Institute for Research in Biomedicine, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland.
Morone D; Institute for Research in Biomedicine, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland.
Paparoditis P; Institute for Research in Biomedicine, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland.
Garzoni C; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland.
Ferrari P; Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland.; Department of Internal Medicine, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.; Prince of Wales Hospital Clinical School, University of New South Wales, Sydney, New South Wales 2052, Australia.
Ceschi A; Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900 Lugano, Switzerland.; Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland.; Clinical Trial Unit, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.; Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, 8091 Zurich, Switzerland.
Neyts J; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium.; Global Virus Network, Baltimore, MD 21201, USA.
Purcell LA; Vir Biotechnology, San Francisco, CA 94158, USA.
Snell G; Vir Biotechnology, San Francisco, CA 94158, USA.
Corti D; Humabs BioMed SA (subsidiary of Vir Biotechnology), 6500 Bellinzona, Switzerland.
Lanzavecchia A; Humabs BioMed SA (subsidiary of Vir Biotechnology), 6500 Bellinzona, Switzerland.; National Institute of Molecular Genetics, 20122 Milano, Italy.
Veesler D; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Howard Hughes Medical Institute, Seattle, WA 98195, USA.
Sallusto F; Institute for Research in Biomedicine, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland.; Institute of Microbiology, ETH Zürich, 8093 Zurich, Switzerland.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2022 Aug 12; Vol. 377 (6607), pp. 735-742. Date of Electronic Publication: 2022 Jul 12.
Typ publikacji:
Journal Article
MeSH Terms:
Angiotensin-Converting Enzyme 2*/chemistry
Antibodies, Monoclonal*/immunology
Antibodies, Monoclonal*/isolation & purification
Antibodies, Viral*/immunology
Antibodies, Viral*/isolation & purification
Broadly Neutralizing Antibodies*/immunology
COVID-19*/immunology
SARS-CoV-2*/immunology
Spike Glycoprotein, Coronavirus*/chemistry
Spike Glycoprotein, Coronavirus*/immunology
Animals ; Humans ; Peptides/immunology ; Protein Binding
Czasopismo naukowe
Tytuł:
Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5.
Autorzy:
Wang Q; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Guo Y; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Iketani S; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.; Department of Microbiology and Immunology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Nair MS; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Li Z; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Mohri H; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Wang M; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Yu J; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Bowen AD; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.; Division of Infectious Diseases, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Chang JY; Division of Infectious Diseases, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Shah JG; Division of Infectious Diseases, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Nguyen N; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Chen Z; AIDS Institute and Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
Meyers K; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.; Division of Infectious Diseases, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Yin MT; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.; Division of Infectious Diseases, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Sobieszczyk ME; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.; Division of Infectious Diseases, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Sheng Z; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Huang Y; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Liu L; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA. .
Ho DD; Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA. .; Department of Microbiology and Immunology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA. .; Division of Infectious Diseases, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA. .
Pokaż więcej
Źródło:
Nature [Nature] 2022 Aug; Vol. 608 (7923), pp. 603-608. Date of Electronic Publication: 2022 Jul 05.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Viral*/immunology
Antibodies, Viral*/therapeutic use
Antigenic Drift and Shift*/genetics
Antigenic Drift and Shift*/immunology
COVID-19*/immunology
COVID-19*/virology
Mutation*
SARS-CoV-2*/classification
SARS-CoV-2*/genetics
SARS-CoV-2*/immunology
Antibodies, Neutralizing/immunology ; Antibodies, Neutralizing/therapeutic use ; COVID-19 Vaccines/immunology ; Humans ; Immunization, Secondary ; Receptors, Virus/metabolism ; Spike Glycoprotein, Coronavirus/genetics ; Spike Glycoprotein, Coronavirus/immunology ; Spike Glycoprotein, Coronavirus/metabolism
Czasopismo naukowe
Tytuł:
Structural basis for the synergistic neutralization of coxsackievirus B1 by a triple-antibody cocktail.
Autorzy:
Zheng Q; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian 361102, People's Republic of China.
Zhu R; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian 361102, People's Republic of China.
Yin Z; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian 361102, People's Republic of China.
Xu L; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian 361102, People's Republic of China.
Sun H; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian 361102, People's Republic of China.
Yu H; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian 361102, People's Republic of China.
Wu Y; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian 361102, People's Republic of China.
Jiang Y; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian 361102, People's Republic of China.
Huang Q; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian 361102, People's Republic of China.
Huang Y; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian 361102, People's Republic of China.
Zhang D; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian 361102, People's Republic of China.
Liu L; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian 361102, People's Republic of China.
Yang H; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian 361102, People's Republic of China.
He M; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian 361102, People's Republic of China.
Zhou Z; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian 361102, People's Republic of China.
Jiang Y; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian 361102, People's Republic of China.
Chen Z; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian 361102, People's Republic of China.
Zhao H; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian 361102, People's Republic of China.
Que Y; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian 361102, People's Republic of China.
Kong Z; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian 361102, People's Republic of China.
Zhou L; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian 361102, People's Republic of China.
Li T; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian 361102, People's Republic of China.
Zhang J; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian 361102, People's Republic of China.
Luo W; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian 361102, People's Republic of China.
Gu Y; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian 361102, People's Republic of China. Electronic address: .
Cheng T; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian 361102, People's Republic of China. Electronic address: .
Li S; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian 361102, People's Republic of China. Electronic address: .
Xia N; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences & School of Public Health, Xiamen University, Xiamen, Fujian 361102, People's Republic of China; Research Unit of Frontier Technology of Structural Vaccinology, Chinese Academy of Medical Sciences, Xiamen, Fujian 361102, People's Republic of China. Electronic address: .
Pokaż więcej
Źródło:
Cell host & microbe [Cell Host Microbe] 2022 Sep 14; Vol. 30 (9), pp. 1279-1294.e6. Date of Electronic Publication: 2022 Aug 23.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Viral*
Pancreatitis*
Animals ; Antibodies, Neutralizing ; Capsid/chemistry ; Capsid Proteins ; Epitopes ; Mice
Czasopismo naukowe
Tytuł:
Evaluation of measles IgM antibody detection assays during the 2018-2019 outbreak in New York State.
Autorzy:
Carson KJ; The Wadsworth Center, New York State Department of Health, Albany, NY, USA.
Tucker HR; The Wadsworth Center, New York State Department of Health, Albany, NY, USA.
Howard K; The Wadsworth Center, New York State Department of Health, Albany, NY, USA.
Hales M; The Wadsworth Center, New York State Department of Health, Albany, NY, USA.
Bryant PW; The Wadsworth Center, New York State Department of Health, Albany, NY, USA.
St George K; The Wadsworth Center, New York State Department of Health, Albany, NY, USA; The Department of Biomedical Sciences, The School of Public Health, The University at Albany, Albany, NY, USA.
Kulas KE; The Wadsworth Center, New York State Department of Health, Albany, NY, USA.
Lee WT; The Wadsworth Center, New York State Department of Health, Albany, NY, USA; The Department of Biomedical Sciences, The School of Public Health, The University at Albany, Albany, NY, USA. Electronic address: .
Pokaż więcej
Źródło:
Diagnostic microbiology and infectious disease [Diagn Microbiol Infect Dis] 2022 Sep; Vol. 104 (1), pp. 115741. Date of Electronic Publication: 2022 Jun 02.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Viral*
Measles*/diagnosis
Measles*/epidemiology
Disease Outbreaks ; Enzyme-Linked Immunosorbent Assay ; Humans ; Immunoglobulin M ; New York/epidemiology ; Sensitivity and Specificity ; Serologic Tests
Czasopismo naukowe
Tytuł:
Effectiveness of the third dose of BNT162b2 vaccine on neutralizing Omicron variant in the Japanese population.
Autorzy:
Kawasuji H; Department of Clinical Infectious Diseases, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Morinaga Y; Department of Microbiology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan; Clinical and Research Center for Infectious Diseases, Toyama University Hospital, Toyama, Japan. Electronic address: .
Tani H; Department of Microbiology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan; Department of Virology, Toyama Institute of Health, Toyama, Japan.
Saga Y; Department of Microbiology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan; Department of Virology, Toyama Institute of Health, Toyama, Japan.
Kaneda M; Department of Clinical Infectious Diseases, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Murai Y; Department of Clinical Infectious Diseases, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Ueno A; Department of Clinical Infectious Diseases, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Miyajima Y; Department of Clinical Infectious Diseases, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Fukui Y; Department of Clinical Infectious Diseases, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Nagaoka K; Department of Clinical Infectious Diseases, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan; Clinical and Research Center for Infectious Diseases, Toyama University Hospital, Toyama, Japan.
Ono C; Laboratory of Virus Control, Center for Infectious Disease Education and Research (CiDER), Osaka University, Osaka, Japan; Laboratory of Virus Control, Research Institute for Microbial Diseases (RIMD), Osaka University, Osaka, Japan.
Matsuura Y; Laboratory of Virus Control, Center for Infectious Disease Education and Research (CiDER), Osaka University, Osaka, Japan; Laboratory of Virus Control, Research Institute for Microbial Diseases (RIMD), Osaka University, Osaka, Japan.
Niimi H; Clinical and Research Center for Infectious Diseases, Toyama University Hospital, Toyama, Japan; Department of Clinical Laboratory and Molecular Pathology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Yamamoto Y; Department of Clinical Infectious Diseases, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan; Clinical and Research Center for Infectious Diseases, Toyama University Hospital, Toyama, Japan.
Pokaż więcej
Źródło:
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy [J Infect Chemother] 2022 Sep; Vol. 28 (9), pp. 1273-1278. Date of Electronic Publication: 2022 Jun 10.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Neutralizing*
Antibodies, Viral*
BNT162 Vaccine*/immunology
COVID-19*/prevention & control
Adult ; Aged ; Humans ; Japan ; Middle Aged ; SARS-CoV-2 ; Vaccines, Inactivated ; Young Adult
SCR Organism:
SARS-CoV-2 variants
Czasopismo naukowe
Tytuł:
Correlates of protection against SARS-CoV-2 infection and COVID-19 disease.
Autorzy:
Goldblatt D; Great Ormond Street Institute of Child Health, University College London, London, UK.
Alter G; Massachusetts General Hospital, Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
Crotty S; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, California, USA.; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego (UCSD), La Jolla, California, USA.
Plotkin SA; University of Pennsylvania, Vaxconsult, Doylestown, Pennsylvania, USA.
Pokaż więcej
Źródło:
Immunological reviews [Immunol Rev] 2022 Sep; Vol. 310 (1), pp. 6-26. Date of Electronic Publication: 2022 Jun 05.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antibodies, Neutralizing*/immunology
Antibodies, Viral*/immunology
COVID-19*/immunology
COVID-19*/prevention & control
SARS-CoV-2*/immunology
Spike Glycoprotein, Coronavirus*/immunology
Epitopes/immunology ; Humans
Czasopismo naukowe
Tytuł:
Age-stratified adeno-associated virus serotype 3 neutralizing and total antibody prevalence in hemophilia A patients from India.
Autorzy:
Daniel HD; Center for Stem Cell Research, Christian Medical College, Vellore, India.; Department of Clinical Virology, Christian Medical College, Vellore, India.
Kumar S; Center for Stem Cell Research, Christian Medical College, Vellore, India.
Kannangai R; Department of Clinical Virology, Christian Medical College, Vellore, India.
J F; Center for Stem Cell Research, Christian Medical College, Vellore, India.
Joel JN; Center for Stem Cell Research, Christian Medical College, Vellore, India.
Abraham A; Department of Hematology, Christian Medical College, Vellore, India.
Lakshmi KM; Department of Hematology, Christian Medical College, Vellore, India.
Agbandje-McKenna M; Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, Florida, USA.
Coleman KE; Powell Gene Therapy Center Toxicology Core, University of Florida, Gainesville, Florida, USA.
Srivastava A; Department of Pediatrics, University of Florida, Gainesville, Florida, USA.
Srivastava A; Center for Stem Cell Research, Christian Medical College, Vellore, India.; Department of Hematology, Christian Medical College, Vellore, India.
Abraham AM; Center for Stem Cell Research, Christian Medical College, Vellore, India.; Department of Clinical Virology, Christian Medical College, Vellore, India.
Pokaż więcej
Źródło:
Journal of medical virology [J Med Virol] 2022 Sep; Vol. 94 (9), pp. 4542-4547. Date of Electronic Publication: 2022 May 31.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Viral*
Hemophilia A*/epidemiology
Hemophilia A*/immunology
Hemophilia A*/therapy
Adult ; Animals ; Antibodies, Neutralizing ; Child ; Dependovirus/genetics ; Genetic Vectors ; Humans ; Prevalence ; Serogroup
Czasopismo naukowe
Tytuł:
Factors associated with anti-SARS-CoV-2 spike antibody titers after a second BNT162b2 mRNA COVID-19 vaccination in Japanese hemodialysis patients.
Autorzy:
Hirai K; Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma-cho, Omiya-ku, Saitama-shi, Saitama-ken, 330-8503, Japan. .
Shimotashiro M; Mizue Yuai Clinic, Tokyo, Japan.
Sonoda T; Mizue Yuai Clinic, Tokyo, Japan.
Okumura T; Mizue Yuai Clinic, Tokyo, Japan.
Ookawara S; Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma-cho, Omiya-ku, Saitama-shi, Saitama-ken, 330-8503, Japan.
Morishita Y; Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma-cho, Omiya-ku, Saitama-shi, Saitama-ken, 330-8503, Japan.
Pokaż więcej
Źródło:
Clinical and experimental nephrology [Clin Exp Nephrol] 2022 Sep; Vol. 26 (9), pp. 925-932. Date of Electronic Publication: 2022 Apr 15.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Viral*/blood
BNT162 Vaccine*/immunology
COVID-19*/prevention & control
Renal Dialysis*
Adult ; Aged ; Aged, 80 and over ; Autoimmune Diseases ; Cross-Sectional Studies ; Female ; Hemoglobins ; Humans ; Japan ; Male ; Middle Aged ; Prospective Studies ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus/immunology ; Vaccination
Czasopismo naukowe
Tytuł:
Low quantity and quality of anti-spike humoral response is linked to CD4 T-cell apoptosis in COVID-19 patients.
Autorzy:
André S; Université Paris Cité, INSERM U1124, F-75006, Paris, France.
Azarias da Silva M; Université Paris Cité, INSERM U1124, F-75006, Paris, France.
Picard M; Université Paris Cité, INSERM U1124, F-75006, Paris, France.
Alleaume-Buteau A; Université Paris Cité, INSERM U1124, F-75006, Paris, France.; Structural and Molecular Analysis Platform, BioMedTech Facilities INSERM US36-CNRS UMS2009, Université Paris Cité, Paris, France.
Kundura L; Laboratoire d'Immunologie, CHU de Nîmes, Nîmes, France.
Cezar R; Laboratoire d'Immunologie, CHU de Nîmes, Nîmes, France.
Soudaramourty C; Université Paris Cité, INSERM U1124, F-75006, Paris, France.
André SC; Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.; ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal.; Department of Internal Medicine, Hospital of Braga, Braga, Portugal.; Clinical Academic Center-Braga, Braga, Portugal.
Mendes-Frias A; Department of Internal Medicine, Hospital of Braga, Braga, Portugal.; Clinical Academic Center-Braga, Braga, Portugal.
Carvalho A; Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.; ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal.; Department of Internal Medicine, Hospital of Braga, Braga, Portugal.; Clinical Academic Center-Braga, Braga, Portugal.
Capela C; Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.; ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal.; Department of Internal Medicine, Hospital of Braga, Braga, Portugal.; Clinical Academic Center-Braga, Braga, Portugal.
Pedrosa J; Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.; ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal.
Gil Castro A; Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.; ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal.
Loubet P; Service des Maladies Infectieuses et Tropicales, CHU de Nîmes, Nîmes, France.
Sotto A; Service des Maladies Infectieuses et Tropicales, CHU de Nîmes, Nîmes, France.
Muller L; Service de Réanimation Chirugicale, CHU de Nîmes, Nîmes, France.
Lefrant JY; Service de Réanimation Chirugicale, CHU de Nîmes, Nîmes, France.
Roger C; Service de Réanimation Chirugicale, CHU de Nîmes, Nîmes, France.
Claret PG; Urgences Médico-Chirugicales Hospitalisation, CHU de Nîmes, Nîmes, France.
Duvnjak S; Service de Gérontologie et Prévention du Vieillissement, CHU de Nîmes, Nîmes, France.
Tran TA; Service de Pédiatrie, CHU de Nîmes, Nîmes, France.
Zghidi-Abouzid O; CHU de Québec-Université Laval Research Center, Québec City, QC, Canada.
Nioche P; Université Paris Cité, INSERM U1124, F-75006, Paris, France.; Structural and Molecular Analysis Platform, BioMedTech Facilities INSERM US36-CNRS UMS2009, Université Paris Cité, Paris, France.
Silvestre R; Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.; ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal.
Corbeau P; Laboratoire d'Immunologie, CHU de Nîmes, Nîmes, France. .; Institut de Génétique Humaine UMR9002 CNRS-Université de Montpellier, Montpellier, France. .
Mammano F; Université Paris Cité, INSERM U1124, F-75006, Paris, France. .; INSERM U1259 MAVIVH, Université de Tours, Tours, France. .
Estaquier J; Université Paris Cité, INSERM U1124, F-75006, Paris, France. .; CHU de Québec-Université Laval Research Center, Québec City, QC, Canada. .
Pokaż więcej
Źródło:
Cell death & disease [Cell Death Dis] 2022 Aug 27; Vol. 13 (8), pp. 741. Date of Electronic Publication: 2022 Aug 27.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Viral*/immunology
CD4-Positive T-Lymphocytes*/cytology
COVID-19*/immunology
Immunity, Humoral*
Apoptosis ; Humans ; Immunoglobulin G ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus/immunology
Czasopismo naukowe
Tytuł:
Age- and sex-based changes in spike protein antibody status after SARS-CoV-2 vaccination and effect of past-infection in healthcare workers in Osaka.
Autorzy:
Hoshida S; Department of Clinical Practice, Yao Municipal Hospital, 1-3-1 Ryuge-cho, Yao, Osaka, 581-0069, Japan. .
Koeda N; Department of Clinical Practice, Yao Municipal Hospital, 1-3-1 Ryuge-cho, Yao, Osaka, 581-0069, Japan.
Hattori H; Department of Clinical Practice, Yao Municipal Hospital, 1-3-1 Ryuge-cho, Yao, Osaka, 581-0069, Japan.
Tanaka M; Department of Clinical Practice, Yao Municipal Hospital, 1-3-1 Ryuge-cho, Yao, Osaka, 581-0069, Japan.
Tanaka I; Department of Clinical Practice, Yao Municipal Hospital, 1-3-1 Ryuge-cho, Yao, Osaka, 581-0069, Japan.
Fukui H; Department of Clinical Practice, Yao Municipal Hospital, 1-3-1 Ryuge-cho, Yao, Osaka, 581-0069, Japan.
Fujita J; Department of Clinical Practice, Yao Municipal Hospital, 1-3-1 Ryuge-cho, Yao, Osaka, 581-0069, Japan.
Sasaki Y; Department of Clinical Practice, Yao Municipal Hospital, 1-3-1 Ryuge-cho, Yao, Osaka, 581-0069, Japan.
Tamura S; Department of Clinical Practice, Yao Municipal Hospital, 1-3-1 Ryuge-cho, Yao, Osaka, 581-0069, Japan.
Pokaż więcej
Źródło:
BMC infectious diseases [BMC Infect Dis] 2022 Aug 26; Vol. 22 (1), pp. 709. Date of Electronic Publication: 2022 Aug 26.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Viral*/blood
COVID-19*/prevention & control
COVID-19 Vaccines*/immunology
Spike Glycoprotein, Coronavirus*/immunology
Female ; Health Personnel ; Humans ; Male ; Middle Aged ; Nucleocapsid Proteins ; SARS-CoV-2 ; Vaccination
Czasopismo naukowe
Tytuł:
Broadly neutralizing antibodies target the coronavirus fusion peptide.
Autorzy:
Dacon C; Antibody Biology Unit, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Tucker C; Antibody Biology Unit, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.; Department of Biology, The Catholic University of America, Washington, DC 20064, USA.
Peng L; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Lee CD; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Lin TH; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Yuan M; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Cong Y; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Wang L; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Purser L; Antibody Biology Unit, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Williams JK; Integral Molecular, Philadelphia, PA 19104, USA.
Pyo CW; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Kosik I; Cellular Biology Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Hu Z; Cellular Biology Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Zhao M; Protein Chemistry Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Mohan D; Antibody Biology Unit, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Cooper AJR; Antibody Biology Unit, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Peterson M; Malaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Skinner J; Malaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Dixit S; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Kollins E; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Huzella L; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Perry D; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Byrum R; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Lembirik S; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Drawbaugh D; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Eaton B; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Zhang Y; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Yang ES; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Chen M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Leung K; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Weinberg RS; New York Blood Center, Lindsley F. Kimball Research Institute, New York, NY 10065, USA.
Pegu A; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Geraghty DE; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Davidson E; Integral Molecular, Philadelphia, PA 19104, USA.
Douagi I; Flow Cytometry Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Moir S; B Cell Immunology Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Yewdell JW; Cellular Biology Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Schmaljohn C; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Crompton PD; Malaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Holbrook MR; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Nemazee D; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Mascola JR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Wilson IA; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.; The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Tan J; Antibody Biology Unit, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2022 Aug 12; Vol. 377 (6607), pp. 728-735. Date of Electronic Publication: 2022 Jul 12.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Monoclonal*/immunology
Antibodies, Viral*/immunology
Broadly Neutralizing Antibodies*/immunology
COVID-19*/immunology
COVID-19*/prevention & control
Epitopes*/chemistry
Epitopes*/immunology
SARS-CoV-2*/immunology
Spike Glycoprotein, Coronavirus*/chemistry
Spike Glycoprotein, Coronavirus*/immunology
COVID-19 Vaccines/chemistry ; COVID-19 Vaccines/immunology ; Humans ; Peptides/immunology ; Protein Conformation, alpha-Helical ; Protein Domains
Czasopismo naukowe
Tytuł:
Antibodies against Spike protein correlate with broad autoantigen recognition 8 months post SARS-CoV-2 exposure, and anti-calprotectin autoantibodies associated with better clinical outcomes.
Autorzy:
Moody R; School of Health and Biomedical Science, STEM College, RMIT University, Bundoora, VIC, Australia.
Sonda S; Tasmanian Vaccine Trial Centre, Clifford Craig Foundation, Launceston General Hospital, Launceston, TAS, Australia.; School of Health Sciences and School of Medicine, University of Tasmania, Launceston, TAS, Australia.
Johnston FH; Public Health Services, Department of Health, Tasmania, TAS, Australia.; Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
Smith KJ; Public Health Services, Department of Health, Tasmania, TAS, Australia.; Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
Stephens N; Tasmanian School of Medicine, University of Tasmania, Hobart, TAS, Australia.
McPherson M; Tasmanian School of Medicine, University of Tasmania, Hobart, TAS, Australia.
Flanagan KL; School of Health and Biomedical Science, STEM College, RMIT University, Bundoora, VIC, Australia.; Tasmanian Vaccine Trial Centre, Clifford Craig Foundation, Launceston General Hospital, Launceston, TAS, Australia.; School of Health Sciences and School of Medicine, University of Tasmania, Launceston, TAS, Australia.
Plebanski M; School of Health and Biomedical Science, STEM College, RMIT University, Bundoora, VIC, Australia.
Pokaż więcej
Źródło:
Frontiers in immunology [Front Immunol] 2022 Aug 11; Vol. 13, pp. 945021. Date of Electronic Publication: 2022 Aug 11 (Print Publication: 2022).
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Viral*/immunology
COVID-19*/complications
COVID-19*/immunology
Spike Glycoprotein, Coronavirus*/immunology
Autoantibodies/immunology ; Autoantigens ; Humans ; Immunoglobulin G ; Leukocyte L1 Antigen Complex/immunology ; SARS-CoV-2
SCR Disease Name:
post-acute COVID-19 syndrome
Czasopismo naukowe
Tytuł:
Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models.
Autorzy:
Cohen AA; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
van Doremalen N; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
Greaney AJ; Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.; Department of Genome Sciences and Medical Scientist Training Program, University of Washington, Seattle, WA 98195, USA.
Andersen H; BIOQUAL, Rockville, MD, USA.
Sharma A; BIOQUAL, Rockville, MD, USA.
Starr TN; Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.; Department of Genome Sciences and Medical Scientist Training Program, University of Washington, Seattle, WA 98195, USA.
Keeffe JR; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Fan C; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Schulz JE; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
Gnanapragasam PNP; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Kakutani LM; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
West AP Jr; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Saturday G; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
Lee YE; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Gao H; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Jette CA; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Lewis MG; BIOQUAL, Rockville, MD, USA.
Tan TK; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK.
Townsend AR; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK.; Chinese Academy of Medical Sciences, Oxford Institute, University of Oxford, Oxford OX3 9DS, UK.
Bloom JD; Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.; Howard Hughes Medical Institute, Seattle, WA 98109, USA.
Munster VJ; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
Bjorkman PJ; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2022 Aug 05; Vol. 377 (6606), pp. eabq0839. Date of Electronic Publication: 2022 Aug 05.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Neutralizing*/immunology
Antibodies, Viral*/immunology
Betacoronavirus*/immunology
Coronavirus Infections*/prevention & control
Epitopes*/chemistry
Epitopes*/immunology
Epitopes*/therapeutic use
Nanoparticles*/therapeutic use
Spike Glycoprotein, Coronavirus*/immunology
Zoonoses*/prevention & control
Zoonoses*/virology
Animals ; Disease Models, Animal ; Macaca ; Mice ; Protein Domains/immunology ; SARS-CoV-2/immunology
SCR Organism:
SARS-CoV-2 variants
Czasopismo naukowe
Tytuł:
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
Autorzy:
Cao Y; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China. .; Changping Laboratory, Beijing, P. R. China. .
Yisimayi A; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.; School of Life Sciences, Peking University, Beijing, P. R. China.
Jian F; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.; College of Chemistry and Molecular Engineering, Peking University, Beijing, P. R. China.
Song W; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.; School of Life Sciences, Peking University, Beijing, P. R. China.
Xiao T; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.; Joint Graduate Program of Peking-Tsinghua-NIBS, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, P. R. China.
Wang L; CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, P. R. China.
Du S; School of Life Sciences, Peking University, Beijing, P. R. China.
Wang J; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.; School of Life Sciences, Peking University, Beijing, P. R. China.
Li Q; Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, P. R. China.
Chen X; Institute for Immunology, College of Life Sciences, Nankai University, Tianjin, P. R. China.
Yu Y; Changping Laboratory, Beijing, P. R. China.; Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, P. R. China.
Wang P; Changping Laboratory, Beijing, P. R. China.
Zhang Z; School of Life Sciences, Peking University, Beijing, P. R. China.
Liu P; School of Life Sciences, Peking University, Beijing, P. R. China.
An R; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.
Hao X; Beijing Ditan Hospital, Capital Medical University, Beijing, P. R. China.
Wang Y; Changping Laboratory, Beijing, P. R. China.
Wang J; Changping Laboratory, Beijing, P. R. China.
Feng R; CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, P. R. China.
Sun H; Changping Laboratory, Beijing, P. R. China.
Zhao L; Changping Laboratory, Beijing, P. R. China.
Zhang W; Beijing Ditan Hospital, Capital Medical University, Beijing, P. R. China.
Zhao D; Beijing Ditan Hospital, Capital Medical University, Beijing, P. R. China.
Zheng J; Changping Laboratory, Beijing, P. R. China.
Yu L; Changping Laboratory, Beijing, P. R. China.
Li C; Changping Laboratory, Beijing, P. R. China.
Zhang N; Changping Laboratory, Beijing, P. R. China.
Wang R; Changping Laboratory, Beijing, P. R. China.
Niu X; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.; College of Chemistry and Molecular Engineering, Peking University, Beijing, P. R. China.
Yang S; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China.; Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, P. R. China.
Song X; Changping Laboratory, Beijing, P. R. China.
Chai Y; Institute for Immunology, College of Life Sciences, Nankai University, Tianjin, P. R. China.
Hu Y; Institute for Immunology, College of Life Sciences, Nankai University, Tianjin, P. R. China.
Shi Y; Institute for Immunology, College of Life Sciences, Nankai University, Tianjin, P. R. China.
Zheng L; Changping Laboratory, Beijing, P. R. China.
Li Z; Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, P. R. China.; Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, P. R. China.
Gu Q; Changping Laboratory, Beijing, P. R. China.
Shao F; Changping Laboratory, Beijing, P. R. China.
Huang W; Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, P. R. China.
Jin R; Beijing Ditan Hospital, Capital Medical University, Beijing, P. R. China.
Shen Z; Organ Transplant Center, NHC Key Laboratory for Critical Care Medicine, Tianjin First Central Hospital, Nankai University, Tianjin, P. R. China. .
Wang Y; Changping Laboratory, Beijing, P. R. China. .; Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, P. R. China. .
Wang X; Changping Laboratory, Beijing, P. R. China. .; CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, P. R. China. .
Xiao J; Changping Laboratory, Beijing, P. R. China. .; School of Life Sciences, Peking University, Beijing, P. R. China. .; Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, P. R. China. .; Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, P. R. China. .
Xie XS; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, P. R. China. .; Changping Laboratory, Beijing, P. R. China. .
Pokaż więcej
Źródło:
Nature [Nature] 2022 Aug; Vol. 608 (7923), pp. 593-602. Date of Electronic Publication: 2022 Jun 17.
Typ publikacji:
Comparative Study; Journal Article
MeSH Terms:
Antibodies, Viral*/immunology
Antigenic Drift and Shift*/genetics
Antigenic Drift and Shift*/immunology
COVID-19*/immunology
COVID-19*/transmission
COVID-19*/virology
Epitopes, B-Lymphocyte*/chemistry
Epitopes, B-Lymphocyte*/genetics
Epitopes, B-Lymphocyte*/immunology
Immune Tolerance*
Mutation*
SARS-CoV-2*/classification
SARS-CoV-2*/genetics
SARS-CoV-2*/immunology
SARS-CoV-2*/metabolism
Angiotensin-Converting Enzyme 2/metabolism ; Antibodies, Monoclonal/immunology ; Antibodies, Neutralizing/immunology ; COVID-19 Vaccines/immunology ; Humans ; Immunity, Humoral ; Immunization, Secondary ; Neutralization Tests ; Spike Glycoprotein, Coronavirus/genetics ; Spike Glycoprotein, Coronavirus/immunology ; Spike Glycoprotein, Coronavirus/metabolism
SCR Organism:
SARS-CoV-2 variants
Czasopismo naukowe
Tytuł:
Antibody response following a Comirnaty booster dose in CoronaVac vaccinated individuals.
Autorzy:
Bochnia-Bueno L; Virology Laboratory, Federal University of Paraná, Curitiba, Brazil; Graduate Program in Microbiology, Parasitology and Pathology, Federal University of Paraná, Curitiba, PR, Brazil.
Nogueira MB; Virology Laboratory, Federal University of Paraná, Curitiba, Brazil.
Genelhoud G; Virology Laboratory, Federal University of Paraná, Curitiba, Brazil.
Raboni SM; Virology Laboratory, Federal University of Paraná, Curitiba, Brazil; Graduate Program in Microbiology, Parasitology and Pathology, Federal University of Paraná, Curitiba, PR, Brazil. Electronic address: .
Pokaż więcej
Źródło:
Diagnostic microbiology and infectious disease [Diagn Microbiol Infect Dis] 2022 Aug; Vol. 103 (4), pp. 115730. Date of Electronic Publication: 2022 May 26.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Viral*
Antibody Formation*
Enzyme-Linked Immunosorbent Assay ; Humans ; Immunization, Secondary
Czasopismo naukowe
Tytuł:
Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022.
Autorzy:
Castilla J; Instituto de Salud Pública de Navarra, Pamplona, Spain.; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.; Navarre Institute for Health Research (IdiSNA), Pamplona, Spain.
Lecea Ó; Gerencia de Atención Primaria, Servicio Navarro de Salud-Osasunbidea, Pamplona, Spain.
Martín Salas C; Navarre Institute for Health Research (IdiSNA), Pamplona, Spain.; Clinical Microbiology Department, Hospital Universitario de Navarra, Pamplona, Spain.
Quílez D; Hospital Reina Sofía, Tudela, Spain.
Miqueleiz A; Navarre Institute for Health Research (IdiSNA), Pamplona, Spain.; Clinical Microbiology Department, Hospital Universitario de Navarra, Pamplona, Spain.
Trobajo-Sanmartín C; Instituto de Salud Pública de Navarra, Pamplona, Spain.; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.; Navarre Institute for Health Research (IdiSNA), Pamplona, Spain.
Navascués A; Navarre Institute for Health Research (IdiSNA), Pamplona, Spain.; Clinical Microbiology Department, Hospital Universitario de Navarra, Pamplona, Spain.
Martínez-Baz I; Instituto de Salud Pública de Navarra, Pamplona, Spain.; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.; Navarre Institute for Health Research (IdiSNA), Pamplona, Spain.
Casado I; Instituto de Salud Pública de Navarra, Pamplona, Spain.; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.; Navarre Institute for Health Research (IdiSNA), Pamplona, Spain.
Burgui C; Instituto de Salud Pública de Navarra, Pamplona, Spain.; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.; Navarre Institute for Health Research (IdiSNA), Pamplona, Spain.
Egüés N; Instituto de Salud Pública de Navarra, Pamplona, Spain.; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.; Navarre Institute for Health Research (IdiSNA), Pamplona, Spain.
Ezpeleta G; Instituto de Salud Pública de Navarra, Pamplona, Spain.
Ezpeleta C; Navarre Institute for Health Research (IdiSNA), Pamplona, Spain.; Clinical Microbiology Department, Hospital Universitario de Navarra, Pamplona, Spain.
Pokaż więcej
Źródło:
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin [Euro Surveill] 2022 Aug; Vol. 27 (33).
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Viral*/blood
COVID-19*/epidemiology
COVID-19*/immunology
Humans ; Nucleocapsid Proteins ; SARS-CoV-2 ; Seroepidemiologic Studies ; Spain/epidemiology ; Spike Glycoprotein, Coronavirus
Czasopismo naukowe
Tytuł:
Hyperimmunized Chickens Produce Neutralizing Antibodies against SARS-CoV-2.
Autorzy:
Aston EJ; Department of Animal Science, College of Agricultural and Environmental Sciences, University of California-Davis, Davis, CA 95616, USA.
Wallach MG; School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, NSW 2007, Australia.
Narayanan A; National Center for Biodefense and Infectious Diseases, George Mason University, Fairfax, VA 22030, USA.
Egaña-Labrin S; Department of Population Health and Reproduction, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616, USA.
Gallardo RA; Department of Population Health and Reproduction, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616, USA.
Pokaż więcej
Źródło:
Viruses [Viruses] 2022 Jul 09; Vol. 14 (7). Date of Electronic Publication: 2022 Jul 09.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Neutralizing*/biosynthesis
Antibodies, Viral*/biosynthesis
Egg Yolk*/immunology
SARS-CoV-2*
Animals ; COVID-19/prevention & control ; Chickens ; Female ; Spike Glycoprotein, Coronavirus
Czasopismo naukowe
Tytuł:
Kinetics of the SARS-CoV-2 Antibody Avidity Response Following Infection and Vaccination.
Autorzy:
Garcia L; Infectious Diseases Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Université Paris Cité, 75015 Paris, France.
Woudenberg T; Infectious Diseases Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Université Paris Cité, 75015 Paris, France.
Rosado J; Infectious Diseases Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Université Paris Cité, 75015 Paris, France.
Dyer AH; Tallaght University Hospital, Tallaght, D24 NR0A Dublin, Ireland.; Department of Medical Gerontology, School of Medicine, Trinity College Dublin, D02 PN40 Dublin, Ireland.
Donnadieu F; Infectious Diseases Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Université Paris Cité, 75015 Paris, France.
Planas D; Virus & Immunity Unit, Department of Virology, Institut Pasteur, Université Paris Cité, 75015 Paris, France.
Bruel T; Virus & Immunity Unit, Department of Virology, Institut Pasteur, Université Paris Cité, 75015 Paris, France.
Schwartz O; Virus & Immunity Unit, Department of Virology, Institut Pasteur, Université Paris Cité, 75015 Paris, France.
Prazuck T; CHR d'Orléans, Service de Maladies Infectieuses, 45100 Orléans, France.
Velay A; CHU de Strasbourg, Laboratoire de Virologie, CEDEX, 67091 Strasbourg, France.; Unité Mixte de Recherche Scientifique Immuno-Rhumathologie Moléculaire (IRM UMR-S) 1109, Strasbourg University, Institut National de la Santé et de la Recherche Médicale (INSERM), CEDEX, 67084 Strasbourg, France.
Fafi-Kremer S; CHU de Strasbourg, Laboratoire de Virologie, CEDEX, 67091 Strasbourg, France.; Unité Mixte de Recherche Scientifique Immuno-Rhumathologie Moléculaire (IRM UMR-S) 1109, Strasbourg University, Institut National de la Santé et de la Recherche Médicale (INSERM), CEDEX, 67084 Strasbourg, France.
Batten I; Department of Medical Gerontology, School of Medicine, Trinity College Dublin, D02 PN40 Dublin, Ireland.
Reddy C; Department of Medical Gerontology, School of Medicine, Trinity College Dublin, D02 PN40 Dublin, Ireland.
Connolly E; Department of Medical Gerontology, School of Medicine, Trinity College Dublin, D02 PN40 Dublin, Ireland.
McElheron M; Department of Medical Gerontology, School of Medicine, Trinity College Dublin, D02 PN40 Dublin, Ireland.
Kennelly SP; Tallaght University Hospital, Tallaght, D24 NR0A Dublin, Ireland.; Department of Medical Gerontology, School of Medicine, Trinity College Dublin, D02 PN40 Dublin, Ireland.
Bourke NM; Department of Medical Gerontology, School of Medicine, Trinity College Dublin, D02 PN40 Dublin, Ireland.
White MT; Infectious Diseases Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Université Paris Cité, 75015 Paris, France.
Pelleau S; Infectious Diseases Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Université Paris Cité, 75015 Paris, France.
Pokaż więcej
Źródło:
Viruses [Viruses] 2022 Jul 08; Vol. 14 (7). Date of Electronic Publication: 2022 Jul 08.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Viral*/immunology
Antibody Affinity*
COVID-19*/prevention & control
SARS-CoV-2*
COVID-19 Vaccines/administration & dosage ; Humans ; Immunoglobulin A ; Immunoglobulin G ; Kinetics ; Pandemics ; Spike Glycoprotein, Coronavirus ; Vaccination
Czasopismo naukowe
Tytuł:
A seroepidemiologic study of a measles outbreak, Yamagata Prefecture, Japan, 2017: The estimation of spreaders using serological assays in a measles elimination setting.
Autorzy:
Seto J; Department of Microbiology, Yamagata Prefectural Institute of Public Health, 1-6-6 Toka-machi, Yamagata, 990-0031, Japan. Electronic address: .
Aoki Y; Department of Microbiology, Yamagata Prefectural Institute of Public Health, 1-6-6 Toka-machi, Yamagata, 990-0031, Japan.
Tanaka S; Department of Microbiology, Yamagata Prefectural Institute of Public Health, 1-6-6 Toka-machi, Yamagata, 990-0031, Japan.
Komabayashi K; Department of Microbiology, Yamagata Prefectural Institute of Public Health, 1-6-6 Toka-machi, Yamagata, 990-0031, Japan.
Ikeda T; Department of Microbiology, Yamagata Prefectural Institute of Public Health, 1-6-6 Toka-machi, Yamagata, 990-0031, Japan.
Mizuta K; Department of Microbiology, Yamagata Prefectural Institute of Public Health, 1-6-6 Toka-machi, Yamagata, 990-0031, Japan.
Pokaż więcej
Źródło:
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy [J Infect Chemother] 2022 Jul; Vol. 28 (7), pp. 1018-1022. Date of Electronic Publication: 2022 Apr 06.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Viral*
Measles*/diagnosis
Measles*/epidemiology
Measles*/prevention & control
Disease Outbreaks ; Humans ; Immunoglobulin G ; Japan/epidemiology ; Measles virus/genetics ; Seroepidemiologic Studies
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies

Prześlij opinię

Twoje opinie są dla nas bardzo ważne i mogą być niezwykle pomocne w pokazaniu nam, gdzie możemy dokonać ulepszeń. Bylibyśmy bardzo wdzięczni za poświęcenie kilku chwil na wypełnienie krótkiego formularza.

Formularz